The use of very low frequency electromagnetic waves with radiotherapy and chemotherapy for treating bladder tumors.

Study of extremely low frequency electromagnetic effect on bladder tumor response with stage II, III, IV and status of T2 - T3A to chemo radiotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013011312124N1

Enrollment

Registered

2013-04-21

Start date

2013-02-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer. Trigone of bladder, Dome of bladder, Lateral wall of bladder, Anterior wall of bladder, Posterior wall of bladder, Bladder neck, Ureteric orifice, Urachus, Overlapping lesion of bladder, Bladder, unspecifie

Interventions

Intervention 1: The use of RTMS device for generating electromagnetic waves with frequency 1HZ in the intervention group. Intervention 2: The use of RTMS device while it is turn off in control group.

Treatment - Other

The use of RTMS device for generating electromagnetic waves with frequency 1HZ in the intervention group

The use of RTMS device while it is turn off in control group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with bladder cancer; Patients without cholecystectomy; Patients with heart, lung problem and... are not candidates for surgery; Patients who are in grades 2, 3, 4 and stage T2 to T3A. Exclusion criteria: Createnine> 1.5; Patients don't have physical ability clinically (performance status>2 ); Patients who are in stage T1 and T4; Patients because of sever leukopenia cannot tolerance the treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Tumor grade. Timepoint: Before of treatment. Method of measurement: Ultrasond, CT, MR, Cystectomy.;Drug dose. Timepoint: Before of treatment and during of treatment. Method of measurement: According to grade and stage of tumor.;Radiation dose. Timepoint: Before of treatment and during of treatment. Method of measurement: According to grade and stage of tumor.;Old. Timepoint: Before of treatment. Method of measurement: Patient's record or interview.;Sex. Timepoint: Before of treatment. Method of measurement: Patient's record or interview.	—

Measure

Time frame

Tumor grade. Timepoint: Before of treatment. Method of measurement: Ultrasond, CT, MR, Cystectomy.;Drug dose. Timepoint: Before of treatment and during of treatment. Method of measurement: According to grade and stage of tumor.;Radiation dose. Timepoint: Before of treatment and during of treatment. Method of measurement: According to grade and stage of tumor.;Old. Timepoint: Before of treatment. Method of measurement: Patient's record or interview.;Sex. Timepoint: Before of treatment. Method of measurement: Patient's record or interview.

—

Secondary

Measure	Time frame
Treatment side effects. Timepoint: Along of treatment. Method of measurement: Visual and blood test.;BUN, Crea, SGOT, SGPT. Timepoint: before treatment and along of treatment. Method of measurement: blood test.;Blood cells count. Timepoint: Before treatment and along of treatment. Method of measurement: Blood test.;Tumor size. Timepoint: Before treatment and middle of treatment and end of treatment. Method of measurement: Ultrasond, CT, MRI, Cystectomy.	—

Measure

Time frame

Treatment side effects. Timepoint: Along of treatment. Method of measurement: Visual and blood test.;BUN, Crea, SGOT, SGPT. Timepoint: before treatment and along of treatment. Method of measurement: blood test.;Blood cells count. Timepoint: Before treatment and along of treatment. Method of measurement: Blood test.;Tumor size. Timepoint: Before treatment and middle of treatment and end of treatment. Method of measurement: Ultrasond, CT, MRI, Cystectomy.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDoctor Bahram Mofid

Urology Nephrology Research Center

mofid429@yahoo.com+98 21 2271 8081

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026